TP53 and acute myeloid leukemia: The by far most important genetic aberration is a mutation in TP53. Patients with MDS who have biallelic TP53-mutations have worse outcomes, such as therapy-refractory disease, rapid progression into AML, and shorter OS, compared to patients with monoallelic mutations [25].